logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

ATLAS: adjuvant axitinib yields uncertain benefit in high-risk RCC

Significant DFS advantage reported by investigators not corroborated by independent review.